LBL-007 + toripalimab + axitinib

**LBL-007 + toripalimab + axitinib** is a pharmaceutical combination under clinical investigation for cancer treatment. LBL-007 is a novel anti-LAG-3 monoclonal antibody aimed at blocking the LAG-3 immune checkpoint, potentially enhancing anti-tumor immune responses. Toripalimab is a humanized IgG4 monoclonal antibody targeting PD-1, acting as an immune checkpoint inhibitor to enhance T-cell mediated anti-tumor immunity. Axitinib is a small molecule tyrosine kinase inhibitor selective for vascular endothelial growth factor receptors (VEGFR-1, -2, and -3), inhibiting angiogenesis and tumor growth. This multi-modal combination is primarily studied for its synergistic effects in increasing anti-tumor activity by combining immune checkpoint blockade with VEGF-driven angiogenesis inhibition. It is being investigated for use in advanced renal cell carcinoma, mucosal melanoma, and other solid tumors[1][2][3][5].

Other names

LBL007LBL-007LBL 007JS001JS-001JS 001Inlyta